Open access
Aug 2026
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.
INTRODUCTION We aimed to achieve consensus on optimal bridging therapy (BT) selection for patients with relapsed/refractory multiple myeloma (RRMM) undergoing chimeric antigen receptor T-cell (CAR-T) therapy. METHODS We conducted a double-blind, three-round modified Delphi panel among U.S.-based hematologist-oncologi...
R. Banerjee, Hamza Hashmi, Preety Chaudhary et al.
· Advances in Therapy · 0 citations